Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Receivables: 2015-2024

Historic Change in Receivables for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $6.1 million.

  • Editas Medicine's Change in Receivables rose 6491.53% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 448.61%. This contributed to the annual value of $6.1 million for FY2024, which is 20.57% up from last year.
  • Per Editas Medicine's latest filing, its Change in Receivables stood at $6.1 million for FY2024, which was up 20.57% from $5.0 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Change in Receivables peaked at $6.1 million during FY2024, and registered a low of -$5.8 million during FY2021.
  • Its 3-year average for Change in Receivables is $5.3 million, with a median of $5.0 million in 2023.
  • In the last 5 years, Editas Medicine's Change in Receivables soared by 1,351.03% in 2020 and then crashed by 202.68% in 2021.
  • Over the past 5 years, Editas Medicine's Change in Receivables (Yearly) stood at $5.6 million in 2020, then slumped by 202.68% to -$5.8 million in 2021, then spiked by 184.38% to $4.9 million in 2022, then climbed by 3.36% to $5.0 million in 2023, then rose by 20.57% to $6.1 million in 2024.